CAD 0.06
(0.0%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -0.06 CAD | 71.35% |
2022 | -0.20 CAD | -156.08% |
2021 | -0.08 CAD | -273.68% |
2020 | -0.02 CAD | -88.29% |
2019 | -0.01 CAD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q1 | 0.00 CAD | 114.23% |
2024 Q3 | -0.01 CAD | -107.69% |
2024 Q2 | -0.00 CAD | -172.22% |
2023 Q2 | -0.02 CAD | -159.34% |
2023 Q1 | -0.01 CAD | 93.93% |
2023 FY | - CAD | 71.35% |
2023 Q4 | -0.03 CAD | -136.45% |
2023 Q3 | -0.01 CAD | 54.66% |
2022 Q1 | -0.01 CAD | 52.36% |
2022 Q4 | -0.15 CAD | -1512.9% |
2022 FY | - CAD | -156.08% |
2022 Q3 | -0.01 CAD | 16.22% |
2022 Q2 | -0.01 CAD | 15.27% |
2021 Q4 | -0.03 CAD | -150.0% |
2021 FY | - CAD | -273.68% |
2021 Q1 | -0.02 CAD | -87.85% |
2021 Q3 | -0.01 CAD | 40.22% |
2021 Q2 | -0.02 CAD | 8.46% |
2020 Q2 | -0.00 CAD | -87.5% |
2020 Q1 | -0.00 CAD | 50.0% |
2020 FY | - CAD | -88.29% |
2020 Q4 | -0.01 CAD | -0.94% |
2020 Q3 | -0.01 CAD | -253.33% |
2019 Q3 | -0.00 CAD | 35.71% |
2019 Q1 | -0.00 CAD | 50.0% |
2019 Q4 | -0.00 CAD | -77.78% |
2019 Q2 | -0.00 CAD | 20.0% |
2019 FY | - CAD | 0.0% |
2018 Q4 | -0.01 CAD | -366.67% |
2018 Q3 | -0.00 CAD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Algernon Pharmaceuticals Inc. | -0.45 CAD | 87.267% |
Asep Medical Holdings Inc | -0.13 CAD | 55.923% |
BetterLife Pharma Inc. | -0.03 CAD | -117.045% |
ChitogenX Inc. | -0.02 CAD | -169.014% |
Rapid Dose Therapeutics Corp. | -0.04 CAD | -39.756% |
Defence Therapeutics Inc. | -0.30 CAD | 80.9% |
Entheon Biomedical Corp. | -0.05 CAD | -12.795% |
Gemina Laboratories Ltd. | -0.07 CAD | 20.417% |
Glow Lifetech Corp. | -0.03 CAD | -98.958% |
Lexston Life Sciences Corp. | -0.02 CAD | -149.13% |
Pharmala Biotech Holdings Inc. | -0.01 CAD | -522.826% |
Doseology Sciences Inc. | -0.08 CAD | 28.105% |
MYND Life Sciences Inc. | -0.03 CAD | -78.505% |
Nova Mentis Life Science Corp. | -0.01 CAD | -590.361% |
PharmaTher Holdings Ltd. | -0.04 CAD | -62.323% |
PreveCeutical Medical Inc. | -0.00 CAD | -2287.5% |
Telescope Innovations Corp. | -0.12 CAD | 52.25% |